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Recent years have seen important advances in our understanding of the etiology, biology and genetics of kidney cancer.
To summarize important achievements and identify prominent research questions that remain, a workshop was organized
by IARC and the US NCI. A series of ‘difficult questions’ were formulated, which should be given future priority in the
areas of population, genomic and clinical research.
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introduction
Recent years have seen important advances in our understanding
of the etiology, biology and genetics of kidney cancer, some of
which have been accompanied by impressive clinical advances.
While these have occurred at a time when the incidence of kidney
cancer among adults continues to increase in North America and
most parts of Europe, elsewhere globally, rates remain stable.
In order to summarize important achievements and identify
prominent research questions that remain for kidney cancer, a
workshop was organized by the International Agency for
Research on Cancer (IARC) and the US National Cancer
Institute (NCI) in the Spring of 2015. Based on a review of major
themes in population, genomic and clinical research, a series of
‘difficult questions’ were formulated, which should be given
future priority within each of these areas.
overview
Worldwide, it is estimated that there are over 300 000 new cases
of kidney cancer per year. Rates are generally lower in most
parts of Asia and Latin America when compared with Europe
and North America [1]. In the United States, kidney cancer inci-
dence varies across distinct populations, with rates highest
among African Americans and lowest among Asian Americans.
In Europe, a particularly notable feature is the strikingly high
rate observed in the Czech Republic, with elevated rates
observed in surrounding regions including Slovakia, the Baltic
countries, eastern Germany and Northern Italy [2], yet there is
no evident explanation to account for this geographic pattern.
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There is also a consistent male to female excess of kidney cancer
observed in both low- and high-incidence regions that is simi-
larly not explained. Understanding these basic epidemiologic
patterns of kidney cancer across the world could lead to insights
into the biological mechanisms that contribute to this malig-
nancy. Genetics and differences in detection of asymptomatic
cases from diagnostic imaging could partially explain these geo-
graphic and ethnic discrepancies, although it is also likely that
exposures and lifestyle choices contribute. The main established
risk factors of kidney cancer are elevated body mass index
(BMI), hypertension and tobacco use [3], which have moderate
estimated effects.
Kidney cancer includes a spectrum of pathologies that can
vary substantively, both with respect to rare inherited and
sporadic forms, although clear cell renal cell carcinoma
(ccRCC) is the most common. Family and population-based
studies have successfully identified key components of the
underlying genetic architecture of susceptibility to kidney
cancer. Family studies have uncovered a series of rare but
highly penetrant mutations, such as in the VHL gene, which
not only have proven to be useful for screening and counsel-
ing in families laden with kidney cancer across generations
but also for highlighting the importance of the VHL pathway
in sporadic ccRCC [4]. Other rare syndromes have revealed
important insights into additional key genes for different
kidney cancer subtypes and together have emerged as a panel
for testing in kidney cancer family screening [5]. Using
genome-wide association studies, it has been possible to
detect a fraction of the common variants conferring suscepti-
bility to kidney cancer; these possess smaller estimated effects
and tend to fall in regulatory regions that have an impact on
redundant, key pathways related to kidney cancer develop-
ment [6–9]. Building on the knowledge of rare mutations and
common variants, it is now possible to begin to build a poly-
genic risk model that will predict the familial risk for family
members of a newly diagnosed case.
The application of new genomic technologies to investigate
the spectrum of somatic alterations in kidney cancer has led to
new insights into a series of events, which could lead to new
therapeutics and possibly earlier detection of kidney cancer.
Large-scale sequence analyses of sets of adult and pediatric
kidney cancers have provided a view of the landscape of the
more common types of events across the genome [10–22].
Adult kidney cancers harbor large numbers of somatic muta-
tions of all classes, from point mutations to structural altera-
tions, whereas in pediatric kidney cancers (e.g. Wilms tumor
and at least half a dozen rarer types), there are fewer somatic
events and in fact, few instances in which a driver mutation has
been identified. The loss of the 3p chromosomal arm, which
harbors the VHL gene, is commonly observed in ccRCC, under-
scoring the importance of the VHL network and its effect
on key metabolic pathways in kidney carcinogenesis. VHL alter-
ation also is the likely reason that VEGF pathway-directed anti-
angiogenic strategies have shown some success. New drivers of
kidney cancer have been identified, partly on the basis of the
frequency of mutations in key genes, and partly on the basis of
corroborative laboratory work [23].
Characterization of rarer types of kidney cancer has led to
new insights, in some instances providing opportunities to
understand how germline mutations inform an understanding
of the somatic alterations. Similarly, initial studies have revealed
the importance of the dynamic genome, known as the epigen-
ome in both adult and in particular, pediatric subtypes of
kidney cancer [24]. In this regard, the microenvironment has
emerged as a critical focus for ongoing research in order to
understand how and in what way the ongoing interaction
between host factors and developing tumors either accelerates or
inhibits tumor formation.
An important characteristic of kidney carcinogenesis is the
role of alterations in metabolic pathways, beginning with
the VHL network [25]. Germline genetic susceptibility (e.g.
both common variants and highly penetrant familial mutations)
has pointed toward VHL and associated genes, such as EPAS1.
Metabolic disruption can directly contribute to kidney cancer
development, both in genomic studies and in laboratory investi-
gations of models, tissue culture and tumor tissue studies. In
parallel with these seminal discoveries has been a strong interest
in characterizing the role of an elevated BMI, perhaps through a
range of metabolic syndromes or disruptions.
The discovery of stable and reproducible biomarkers for risk
or earlier diagnosis of kidney cancer using germline genetics or
serum/urinary biomarkers remains a daunting challenge. Many
small studies have provided preliminary observations but in
larger datasets, the utility of candidate or pathway analyses
remains elusive. Such molecular epidemiologic studies could
provide insight into mechanisms of kidney cancer development
and improve prediction models. Our capacity to achieve these
goals will be based on increasing the scope of our understanding
of mutations and biomarkers applied to substantively larger
investigations, preferably using prospectively collected biospeci-
mens in order to identify markers of risk.
Therapeutic approaches to kidney cancer have blossomed in
the last decade, fueled by new targeted therapies (e.g. designer
drugs that attack specific proteins or pathways critical for angio-
genesis and immune regulation). There are more than half a
dozen new-targeted agents in use for metastatic cases, many
showing impressive initial responses, but resistance is invariably
observed which limits the ability to impact long-term survival
[26]. Proteomic and circulating biomarker studies have provided
promising leads for understanding determinants of tumor pro-
gression and metastases, a major problem in kidney cancer.
Immunotherapy for kidney cancer has progressed from cytokine-
based therapies to PD-1 and PDL-1 blockade. Many exciting
reports have detailed successful applications of immunotherapy,
with a recent phase 3 trial showing longer survival in patients
receiving this new treatment [27]. More studies will be needed to
advance this exciting component of precision medicine, particu-
larly as it relates to selection of patients with a high probability of
response to therapy.
future directions
The exciting trends in molecular characterization and targeted
therapy of kidney cancer should be matched with a new
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commitment to understanding the etiology and pathogenesis of
this malignancy. How and why there are major differences by
sex, race, geography and exposure histories underscores the
complexity of kidney cancer etiology. Global assessment of inci-
dence but also outcomes of therapeutic approaches could reveal
important observations that, in turn could inform both the
underlying biology and identify new targets for early detection
or therapy. The shift toward molecular characterization of adult
and pediatric cancers has uncovered a series of important ques-
tions related to the key pathways underlying the spectrum of
kidney cancer. Heterogeneity in somatic changes has emerged
as a significant challenge in kidney cancer, revealing that distinct
molecular phenotypes within an individual’s tumour may have
to be targeted in parallel, unless there is a common somatic muta-
tion that can be targeted upstream [28]. Moreover, the analysis of
somatic signatures could reveal important clues to environmental
and lifestyle factors that contribute to kidney cancer [16, 29].
Over the past two decades, the detection of germline sus-
ceptibility alleles, both common and rare, has accelerated
our understanding of the underlying genetic architecture of
how kidney cancer develops. The new tools of genome-wide
association and next-generation sequencing studies should
continue to be applied to progressively larger and better-
annotated datasets to further add to the comprehensive
catalog of susceptibility alleles. The utility of sequencing
subsets of newly diagnosed cases of kidney cancers has already
emerged as a compelling argument and merits further investi-
gation, particularly in families or outliers (such as younger
cases of ccRCC or the spectrum of rare subtypes). Similar
commitment to the genetics of pediatric forms of kidney
cancer could be useful for future screening approaches,
especially in high-risk settings. It will be important to conduct
these studies in populations with different genetic histories
and exposures. The ability to examine gene–environment
interactions either directly or through the approach of
Mendelian randomization should be a high priority for dis-
covery of new relationships, some of which could be harnessed
for detection or prevention [30].
Further characterization of the genomic landscape of kidney
cancers, including larger numbers of rarer cancers, should
provide an important foundation for identifying the catalog of
driver events. While The Cancer Genome Atlas (TCGA) and
International Cancer Genome Consortium (ICGC) have pro-
vided an impetus to conduct large-scale characterization pro-
jects, the international community should develop a shared data
resource to combine academic, clinical and research resources to
rapidly accelerate the bioinformatics analyses of the spectrum of
kidney cancer. So far, the number of samples studied has led to
the identification of genes that are commonly mutated. As
kidney cancer has emerged as one of the pivotal examples of
tumor heterogeneity, together with its spectrum of rare and
common subtypes, many more tumor/normal pairs will require
characterization in order to capture key events, both for targets
and for prognostic factors [31]. The next generation of genomic
characterization efforts should be conducted in studies that have
collected both epidemiologic risk factors, including pre-diagnos-
tic biomarkers when possible, and extensive annotation of the
clinical parameters including long-term outcome. The investiga-
tion of somatic alterations with clinical outcomes should be a
high priority, including detailed analyses of tumor heterogen-
eity, which might require regional sampling guided by imaging.
The challenge of heterogeneity has important implications for
therapeutic decisions, and perhaps in the future, therapeutic
monitoring, especially if circulating tumor DNA or tumor
cells can be adapted as an efficient and widespread technique.
Current approaches to develop models for the evolution of
kidney cancer represent an important parallel approach, one
that should be iteratively coordinated with clinical characteriza-
tion of the cancer genome and its epigenomic changes [28].
Serial and regional biopsies in well-characterized biorepositories
should be available and include detailed follow-up on outcomes,
therapeutic interventions and new imaging techniques. A
critical question of the future will be how and in what way
imaging-based techniques can be harmonized with genomic
technologies to identify targets, but equally new target identifi-
cation will need to be combined with the parallel development
of predictive genomic and proteomic biomarkers to enable
patient stratification.
The rapid acceleration of immune-based therapies should
remain a major focus of kidney cancer research, providing new
insights into how and in what way the immune system could
better conduct surveillance against emerging cancers and to
treat kidney cancer. The collective assessment of the different
strategies could shed light on prognostic factors, such as the
HLA haplotypes and circulating biomarkers. Eventually, the use
of immunotherapy may be a central component in the arma-
mentarium of precision medicine tools. Determinants of
immune-based therapeutic success should provide new insights
into stratification of individual patients, perhaps based on emer-
ging immune profiles of both measured biomarkers and genetic
predisposition.
In conclusion, the tools of genomic characterization and
targeted therapy have begun to accelerate the investigation of
the basic biology of kidney cancer, thus providing novel
approaches toward improving early detection, intervention
and monitoring this malignancy. The development of a
more refined molecular taxonomy of the spectrum of kidney
cancer will advance most efficiently if the community con-
tinues to develop more robust approaches to data sharing.
Interoperability between data resources should remain a
central goal both for resources generated by ‘-omic’ technolo-
gies and more precise phenotyping, based on sound epide-
miologic and clinical practice. By integrating datasets, the
opportunity to determine shared and unique features should
benefit the diagnosis, treatment and monitoring of rare and
common kidney cancers alike. In the distant future, it may
emerge that precision prevention strategies are possible, but
they will be based on further research in all corners of the
globe.
 | Scelo et al. Volume 27 | No. 8 | August 2016
special articles Annals of Oncology
Difficult questions that should be prioritized
1 What factors explain the geographical, racial/ethnic and sex
differences in the incidence of kidney cancer?
2 What underlying biologic pathways drive the association with
kidney cancer risk for obesity and hypertension?
3 Can a greater understanding of germline variation of kidney
cancer inform us about the unknown lifestyle and
environmental causes?
4 Can a better understanding of the somatic signatures (both
genomic and proteomic) of kidney cancer and its subtypes
provide clues to etiologic risk factors and prognosis?
5 How is response to targeted therapy and immunotherapy
influenced by epigenetic variation?
6 With more than a half a dozen approved drugs targeting the
VHL/HIF pathway in clear cell renal cell carcinomas, what
are the next steps toward improving therapy and survival in
both early and advanced cases?
7 What are the barriers for rapid data sharing of sequencing of
kidney cancers, which could accelerate identification and
characterization of drivers of oncogenesis?
8 How do we select kidney cancer patients for constitutional
genetic testing, beyond those fitting a ‘classic’ kidney cancer
susceptibility syndrome?
9 Why do more than half of pediatric Wilms tumors lack
identifiable driver mutations and what does this suggest
about epigenetic regulation?
10 What new data are critical to develop more accurate models for
understanding genomic and epigenetic changes across the
spectrum of renal cancers?
11 Are current pathological subtype classifications still clinically
relevant?
12 What factors can reliably predict durable response to
immunotherapy?
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